VolitionRx Offers a Enterprise Update and Appoints Vital Officers to Push Commercialization Attempts

AUSTIN, Texas, Feb. 2, 2021 /PRNewswire/ — VolitionRx Minimal (NYSE AMERICAN: VNRX) (“Volition”) now offered a small business update and announced the appointment of a new Chief Fiscal Officer, Mr. Terig Hughes, in addition to the appointment of Dr. Gaetan Michel as Chief Operating Officer, Mr. Gael Forterre as Chief Business Officer, and Dr. Mark Eccleston as Chief Know-how Officer.

 “Regardless of the pandemic we achieved a whole lot all over 2020 and the momentum has continued into 2021 with a extremely fast paced January. We have opened our new manufacturing facility “Silver 1”, introduced extra non-dilutive funding of around $4 million and offered the first data from our large-scale lung cancer research,” commented Cameron Reynolds, President and Team Main Executive Officer. “As we transition from a study and improvement company to a commercial firm, we are delighted to reinforce the leadership staff with the appointment of Terig and Gael and the effectively-deserved promotions of Gaetan and Mark. All 4 convey robust worldwide know-how and practical experience to their respective roles and these appointments intention to present a incredibly strong item target to our management workforce. Be sure to consider a number of minutes to enjoy the movie below for a business update and to fulfill the new associates of our management workforce.”

Mr. Reynolds included, “We would also like to thank Mr. David Vanston, our previous Chief Financial Officer, for his contributions to Volition in the course of his tenure with us and we want him very well in his long run endeavors.”

Observe a online video offering a business enterprise update and introducing Volition’s new staff members here  – https://youtu.be/JznLeU0UOtg&#13

Mr. Hughes, our new Chief Money Officer, is a seasoned finance experienced with more than 20-five decades of accounting, finance and small business management experience attained via an international career spanning the United States, Europe and Asia and joins Volition from AUM Biosciences Pte. Ltd., a quick-increasing biotechnology corporation centered on creating novel most cancers prescription drugs, exactly where he acted as Main Financial Officer since 2018. Prior to then, Mr. Hughes held a number of senior leadership positions at Elsevier, a division of RELX Team plc, a FTSE 100 organization, which includes regional Managing Director and regional Finance Director for Elsevier Well being Solutions. He has substantial experience in economical reporting, scheduling & analysis, and profit and reduction management, as well as product commercialization, licensing and distributor management.

Mr. Hughes holds a Bachelor’s degree in Accounting and Legislation from De Montfort University, Leicester, United kingdom.

Commenting on his appointment Mr. Hughes claimed, “I am delighted to sign up for Volition at this enjoyable time, not only will solution launches enable saves life as a result of earlier diagnosis they should really also aid give prolonged term benefit for our stockholders.”

Mr. Gael Forterre, our new Main Commercial Officer, has over 15 decades of encounter investing in and scaling rapidly expanding providers. Mr. Forterre started out his profession as a hedge fund analyst in Paris and worked in a selection of investment banking and buying and selling roles in excess of 10 furthermore years, like launching Armori Funds Management LLC in 2014, for which he done a substantial range of investments on behalf of family members workplaces/institutional investors and turned energetic in supporting the expansion of its portfolio companies.  Most not long ago, from 2017 until eventually joining Volition, he served as the Chief Executive Officer of Ucroo Included, a rapid-rising collaboration and conversation technologies corporation, which he led to a tripling in profits development two a long time in a row.  Mr. Forterre continues to provide as a board member of Ucroo Included and Post22.

Mr. Forterre holds a Master’s diploma in finance from Sorbonne Paris I and a double MBA from Columbia Company Faculty and the London Small business College. &#13

“Just after much more than 15 decades of investing and serving to corporations scale, I obtain Volition to have the most persuasive likely,” commented Mr. Forterre, “and am delighted to join the passionate staff to generate commercialization of the product or service pipeline.”

Mr. Forterre will aim on making a solid commercialization program and workforce to travel the extensive range of goods to be formulated working with the Nu.Q™ platform.

Dr. Gaetan Michel, our new Chief Operating Officer, has been with Volition almost seven a long time, formerly serving as Main Working Officer of Belgian Volition and at the moment as Main Executive Officer of Belgian Volition. With around 15 years of task management, manufacturing and operational encounter, Dr. Michel is preferably placed to oversee and increase Volition’s worldwide operations like the newly opened Innovation Hub in San Diego, the production facility “Silver A person” and Exploration and Advancement Facility in Belgium, as effectively as expanding the veterinary subsidiary in Texas, U.S.A.

“I am honored to accept the placement of Main Working Officer of Volition,” commented Dr. Michel, ” and search forward to executing our enlargement programs all over 2021 and over and above as we roll out our Nu.Q™ platform globally.”

Dr. Mark Eccleston, a single of Volition’s founding scientists will now provide as our new Chief Technology Officer. Dr. Eccleston has over 20 years’ knowledge in the biotechnology sector and holds a PhD in Polymer Chemistry for biomedical applications. In this new position, he will recognize and evaluate new and modern infrastructures which will help in the deployment of Volition’s proprietary Nu.Q™ system.&#13

“Soon after ten many years with Volition it is continue to greatly satisfying working on this sort of a slicing-edge technologies,” commented Dr. Eccleston, “Nu.Q™ not only has the prospective to help diagnose most cancers, but probably numerous other critical ailments. I appear forward to this new position in which I can participate in a critical section in evaluation and sourcing the technological know-how platforms that can support with a assortment of Nu.Q™ item launches.”  

For more information remember to get in touch with mediarelations@volition.com.

About Volition

Volition is a multi-national epigenetics firm developing straightforward, easy to use, cost productive blood assessments to aid diagnose a selection of cancers and other health conditions. Early prognosis has the prospective to not only extend the lifetime of clients, but also to increase their top quality of lifestyle. The tests are based on the science of Nucleosomics^TM, which is the follow of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an sign that disease is existing. Volition is primarily focused on human diagnostics but also has a subsidiary concentrated on animal diagnostics.

Volition’s study and growth pursuits are centered in Belgium, with a little laboratory in California and further workplaces in Texas, London and Singapore, as the company focuses on bringing its diagnostic merchandise to market.&#13

For extra data about Volition, check out Volition’s web page volition.com or link with us through:

Twitter: https://twitter.com/volitionrx

LinkedIn: https://www.linkedin.com/business/volitionrx

Facebook: https://www.facebook.com/VolitionRx/

YouTube: https://www.youtube.com/user/VolitionRx&#13

The contents found at Volition’s web-site address, Twitter, LinkedIn, Fb, and YouTube are not included by reference into this doc and really should not be regarded as portion of this doc.  The addresses for Volition’s website, Twitter, LinkedIn, Fb, and YouTube are involved in this doc as inactive textual references only.

Media / Investor Contacts

Secure Harbor Assertion&#13

Statements in this press release may be “ahead-searching statements” inside of the that means of Portion 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Exchange Act of 1934, as amended, that issue issues that contain risks and uncertainties that could trigger genuine final results to vary materially from individuals expected or projected in the forward-hunting statements. Terms this sort of as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “indicates,” “could,” “would,” “should really,” “may,” “will” and related expressions recognize forward-hunting statements. These forward-seeking statements relate to the efficiency of Volition’s blood-centered diagnostic and prognostic checks, and Volition’s capacity to produce and efficiently commercialize these kinds of exam platforms for early detection of cancer and other health conditions. Volition’s precise results may well differ materially from those indicated in these ahead-on the lookout statements due to numerous hazards and uncertainties, such as, devoid of limitation, benefits of studies testing the efficacy of its exams. For instance, if Volition fails to develop and commercialize diagnostic or prognostic products, it may possibly be unable to execute its prepare of functions. Other pitfalls and uncertainties involve Volition’s failure to attain vital regulatory clearances or approvals to distribute and sector long run items a failure by the market to take the solutions in Volition’s progress pipeline or any other diagnostic or prognostic products and solutions Volition may well produce Volition’s failure to safe suitable intellectual assets security Volition will facial area fierce competition and Volition’s meant products and solutions could turn into out of date because of to the hugely competitive character of the diagnostics market place and its swift technological transform downturns in domestic and international economies and other challenges identified in Volition’s most current Yearly Report on Kind 10-K and Quarterly Reports on Kind 10-Q, as nicely as other paperwork that Volition data files with the Securities and Exchange Fee. These statements are based on recent anticipations, estimates and projections about Volition’s small business dependent, in component, on assumptions made by administration. These statements are not ensures of foreseeable future general performance and involve threats, uncertainties and assumptions that are challenging to predict. Ahead-on the lookout statements are made as of the day of this launch, and, other than as required by law, Volition does not undertake an obligation to update its ahead-seeking statements to mirror long run occasions or circumstances.

Pursuant to the disclosure requirements of the NYSE American Business Manual Area 711(a), Volition is reporting that its Board of Administrators (together with all of its unbiased administrators) has accredited the issuance of a warrant to acquire up to 185,000 shares of Volition popular inventory (the “Warrant”) to Mr. Terig Hughes as a content inducement for his coming into employment with Singapore Volition Pte. Constrained, Volition’s wholly-owned subsidiary, as Chief Economical Officer and Treasurer. The Warrant has an work out cost of $4.90 per share and is exercisable commencing February 1, 2022 (matter to (i) continued employment by these date, and (ii) the shares underlying the Warrant shall have been duly permitted for listing by the NYSE American prior to workout) with an expiration day of February 1, 2027.

Nucleosomics™ and Nu.Q™ and their respective logos are logos and/or provider marks of VolitionRx Confined and its subsidiaries. All other logos, provider marks and trade names referred to in this push release are the assets of their respective owners.

Look at initial articles to obtain multimedia:https://www.prnewswire.com/news-releases/volitionrx-provides-a-business enterprise-update-and-appoints-vital-officers-to-push-commercialization-attempts-301219947.html

Supply VolitionRx Ltd